<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="189">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00874770</url>
  </required_header>
  <id_info>
    <org_study_id>AI444-014</org_study_id>
    <secondary_id>EUDRACT# 2009-010149-29</secondary_id>
    <nct_id>NCT00874770</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)</brief_title>
  <official_title>A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <authority>France: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify 1 or more doses of daclatasvir, which when used in
      combination with pegylated interferon alpha and ribavirin, are safe and demonstrate
      sufficient anti-hepatitis C virus activity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Participants With Extended Rapid Virologic Response (eRVR) at Weeks 4 and 12</measure>
    <time_frame>A Weeks 4 and 12</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>eRVR was defined as undetectable hepatitis C virus RNA less than the lower limit of detection (10 IU/mL) at Weeks 4 and 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Rapid Virologic Response (RVR) at Week 4</measure>
    <time_frame>At Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>RVR was defined as undetectable hepatitis C virus (HCV) RNA ie, HCV RNA less than the lower limit of detection (10 IU/mL) at Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Early Virologic Response (EVR) at Week 12</measure>
    <time_frame>At Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>EVR was defined as a ≥2 log10 decrease in hepatitis C virus (HCV) RNA from baseline at Week 12 , or HCV RNA &lt;10 IU/mL for participants with baseline HCV RNA &lt;1000 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Complete Early Virologic Response (cEVR) at Week 12</measure>
    <time_frame>At Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>cEVR was defined as hepatitis C virus RNA &lt;10 IU/mL at Week 12</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), and Treatment-related AEs and Who Died in Treatment Phase</measure>
    <time_frame>SAE: From Day 1 up to 30 days after last dose of study drug, AE: From Day 1 to 7 days after last dose of study drug</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>An AE was defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a patient or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life-threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization. Treatment-related AE was defined as an AE that had certain, probable, possible, or unknown relationship to study drug.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), and Treatment-related AEs and Who Died in Follow-up Period</measure>
    <time_frame>From Day 31 up to Week 24 of post treatment follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>An AE was defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a patient or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life-threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization. Treatment-related AE was defined as an AE that had certain, probable, possible, or unknown relationship to study drug.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Grade 3 to 4 Abnormalities on Laboratory Test Results</measure>
    <time_frame>From screening up to Week 12 (treatment period)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Clinically significant change in marked laboratory abnormalities (Grade 3 to 4 ) included: Alanine aminotransferase (ALT)- Grade 3 as &gt;5.0 to 10.0* Upper Limit of Normal (ULN), Grade 4 as &gt;10.0*ULN; Aspartate aminotransferase (AST)- Grade 3 as &gt;5.0 to 10.0*ULN, Grade 4 as &gt;10.0*ULN; Hemoglobin- Grade 3 as 7.0 to 8.9 g/dL, Grade 4 as &lt;7.0 g/dL; Neutrophils- Grade 3 as 0.5 to 0.749*10^9/L, Grade 4 as &lt;0.5*10^9/L; Lymphocytes- Grade 3 as 0.35 to 0.499*10^9/L, Grade 4 as &lt;0.35*10^9/L; Total Bilirubin- Grade 3 as 2.6-5.0*ULN, Grade 4 as &gt;5.0*ULN; Platelets- Grade 3 as 25000 to 49999*10^9/L, Grade 4 as &lt;25000 10^9/L and white blood cells (WBC) - Grade 3 as 1000 to 1499*10^9/L, Grade 4 as &lt;1000*10^9/L.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daclatasvir, Peginterferon alpha-2a, ribavirin (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daclatasvir, Peginterferon alpha-2a, ribavirin (C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Peginterferon alpha-2a, ribavirin (D)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <description>Tablets, oral, 3 mg, Daily, 48 weeks</description>
    <arm_group_label>Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <description>Tablets, oral, 10 mg, Daily, 48 weeks</description>
    <arm_group_label>Daclatasvir, Peginterferon alpha-2a, ribavirin (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <description>Tablets, oral, 60 mg, Daily, 48 weeks</description>
    <arm_group_label>Daclatasvir, Peginterferon alpha-2a, ribavirin (C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet, oral, 0 mg, Daily 48 weeks</description>
    <arm_group_label>Placebo, Peginterferon alpha-2a, ribavirin (D)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alpha-2a</intervention_name>
    <description>Syringe, subcutaneous, 180 µg, Weekly, 48 weeks</description>
    <arm_group_label>Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A)</arm_group_label>
    <arm_group_label>Daclatasvir, Peginterferon alpha-2a, ribavirin (B)</arm_group_label>
    <arm_group_label>Daclatasvir, Peginterferon alpha-2a, ribavirin (C)</arm_group_label>
    <arm_group_label>Placebo, Peginterferon alpha-2a, ribavirin (D)</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
    <description>Tablet, oral, 1000 or 1200 mg, based on weight, Daily, 48 weeks</description>
    <arm_group_label>Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A)</arm_group_label>
    <arm_group_label>Daclatasvir, Peginterferon alpha-2a, ribavirin (B)</arm_group_label>
    <arm_group_label>Daclatasvir, Peginterferon alpha-2a, ribavirin (C)</arm_group_label>
    <arm_group_label>Placebo, Peginterferon alpha-2a, ribavirin (D)</arm_group_label>
    <other_name>Copegus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Patients chronically infected with hepatitis C virus (HCV) genotype 1

          -  HCV RNA viral load of ≥10*5* IU/mL (100,000 IU/mL) at screening

          -  Treatment naive

        Key Exclusion Criteria:

          -  Women of child-bearing potential

          -  Cirrhosis

          -  Coinfection with HIV or hepatitis B virus
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Liver &amp; Digestive Specialists (Alds)</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Colorado Denver &amp; Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School Of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Llc Dba The Research Institute</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Center For Liver Disease</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Consultants</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Options Health Research, Llc</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Texas Research Institute</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Research</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
  </removed_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trials Disclosure</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 23, 2015</lastchanged_date>
  <firstreceived_date>April 2, 2009</firstreceived_date>
  <firstreceived_results_date>August 6, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antivirals</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
